The dual presence at ASCRS with both expert engagement and data presentation signals strong momentum for urcosimod. Traders should monitor the April 11 data presentation for additional efficacy details that could catalyze investor interest ahead of the planned Phase 2b/3 trial.
Price Chart
Executive Summary
OKYO Pharma announced a Scientific Advisory Board meeting with ophthalmology experts and a data presentation on its lead candidate urcosimod at the 2026 ASCRS Annual Meeting. The company highlighted positive Phase 2 data and plans to initiate a Phase 2b/3 trial for neuropathic corneal pain.
Key Facts
- OKYO Pharma will hold a Scientific Advisory Board meeting with leading ophthalmology experts during the 2026 ASCRS Annual Meeting.
- Dr. Pedram Hamrah will present Phase 2 efficacy and safety data for urcosimod in neuropathic corneal pain on April 11, 2026.
- Urcosimod has received Fast Track designation from the FDA and is the first investigational therapy with an IND specifically for neuropathic corneal pain.
- The company recently completed a successful Phase 2 trial in NCP and plans to initiate a 150-patient Phase 2b/3 trial in the first half of 2026.
- Urcosimod showed statistically significant results in a prior 240-patient Phase 2 trial for dry eye disease.
Financial Impact
No direct financial impact disclosed, but advancement in clinical development increases potential valuation
Risk Factors
- Clinical trial results may not replicate prior positive signals
- Regulatory delays despite Fast Track designation
- Small market cap ($53M) increases volatility risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001493152-26-015411 |
| Exhibit: ex99-1.htm | 0001493152-26-015411 |
| Document: 0001493152-26-015411-index-headers.html | 0001493152-26-015411 |
| Document: 0001493152-26-015411-index.html | 0001493152-26-015411 |
| Document: 0001493152-26-015411.txt | 0001493152-26-015411 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 21d ago | 6-K | $1.46 $1.41 | ▼ −3.42% | ▼ −3.18% | $1.49 (+2.05%) |
Oct 6, 2026 21d ago | Press Release | $1.46 $1.41 | ▼ −3.42% | ▼ −3.18% | $1.49 (+2.05%) |
Sep 29, 2026 28d ago | 6-K | $1.36 $1.29 | ▼ −5.15% | ▼ −4.94% | $1.49 (+9.56%) |
Sep 8, 2026 7w ago | 6-K | $1.53 $1.45 | ▼ −5.23% | ▼ −4.76% | $1.49 (−2.61%) |
Aug 7, 2026 11w ago | Insider Cluster | $1.57 $1.52 | ▼ −3.18% | ▼ −2.87% | $1.49 (−5.10%) |
Jul 28, 2026 13w ago | 6-K | $1.64 $1.64 | · 0.00% | ▲ +1.54% | $1.49 (−9.15%) |
Jul 27, 2026 13w ago | 6-K | $1.64 $1.64 | · 0.00% | ▼ −0.24% | $1.49 (−9.15%) |
Jul 23, 2026 13w ago | 6-K | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.49 (+0.68%) |
Jul 23, 2026 13w ago | Press Release | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.49 (+0.68%) |
Jul 23, 2026 13w ago | 6-K | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.49 (+0.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers